Department of Thoracic Surgery, University College London Hospitals (UCLH), London, UK.
Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500, Larissa, Biopolis, Greece.
Gen Thorac Cardiovasc Surg. 2021 May;69(5):832-842. doi: 10.1007/s11748-020-01549-2. Epub 2020 Nov 22.
Malignant pleural effusion is a severe and common complication in patients with primary or metastatic malignancies of the pleura. Although talc pleurodesis is widely used for managing malignant pleural effusions, there is still controversy in the literature regarding its superiority compared to other approaches. We conducted this meta-analysis to further investigate its efficacy compared to alternative interventions.
We systematically reviewed the PubMed, Cochrane, and Scopus databases to identify studies that fulfilled our inclusion criteria. Study quality was evaluated using validated tools and the pooled Risk Ratio (RR) and confidence interval (CI) were calculated. We performed sensitivity analyses based on the meta-analysis method and type of study.
Twenty-four studies were included in the current systematic review meta-analysis. Talc pleurodesis was associated with statistically significant higher successful pleurodesis rates when compared with all controls [RR (95% CI) 1.15 (1.00, 1.31); P = 0.04], only chemical controls [RR (95% CI) 1.26 (1.13, 1.40); P < 0.0001], and bleomycin [RR (95% CI) 1.22 (1.05, 1.42); P = 0.008]. The comparison between talc pleurodesis and controls at the > 1-month follow-up time point favored talc pleurodesis [RR (95% CI): 1.62 (1.15, 2.27); P = 0.005]. Finally, talc poudrage was associated with a statistically significant higher successful pleurodesis rate when compared with all controls. Sensitivity analyses verified the robustness of our results.
Talc pleurodesis is an effective MPE management approach presenting borderline statistically significant superiority compared to control methods especially compared to bleomycin as well as when pleurodesis success is evaluated later than 1 month postoperatively.
恶性胸腔积液是胸膜原发性或转移性恶性肿瘤患者的一种严重且常见的并发症。滑石粉胸膜固定术广泛用于治疗恶性胸腔积液,但在文献中仍存在其与其他方法相比具有优越性的争议。我们进行了这项荟萃分析,以进一步研究其与替代干预措施相比的疗效。
我们系统地检索了 PubMed、Cochrane 和 Scopus 数据库,以确定符合我们纳入标准的研究。使用经过验证的工具评估研究质量,并计算汇总风险比(RR)和置信区间(CI)。我们根据荟萃分析方法和研究类型进行了敏感性分析。
当前系统评价荟萃分析纳入了 24 项研究。与所有对照组相比,滑石粉胸膜固定术与统计学上更高的胸膜固定成功率相关[RR(95%CI)1.15(1.00,1.31);P=0.04],与仅化学对照组相比[RR(95%CI)1.26(1.13,1.40);P<0.0001],与博来霉素相比[RR(95%CI)1.22(1.05,1.42);P=0.008]。在随访时间超过 1 个月的时间点,滑石粉胸膜固定术与对照组的比较更倾向于滑石粉胸膜固定术[RR(95%CI):1.62(1.15,2.27);P=0.005]。最后,与所有对照组相比,滑石粉粉末更能显著提高胸膜固定成功率。敏感性分析验证了我们结果的稳健性。
滑石粉胸膜固定术是一种有效的恶性胸腔积液管理方法,与对照组相比具有统计学上的优势,尤其是与博来霉素相比,并且在术后 1 个月后评估胸膜固定成功率时优势更为明显。